Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HK1 | P19367 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | GALK1 | P51570 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13279465 | 0.78 | MAPT (0.41) | MAPTNPC1AHRPDK2KDM4E | |
| SCHEMBL19678 | 0.76 | — | — | |
| SCHEMBL8685779 | 0.74 | MAPT (0.35) | MAPTNPC1AHRPDK2KDM4E | |
| SCHEMBL3937255 | 0.72 | CHRNB2 (0.38) | — | |
| SCHEMBL1162905 | 0.68 | TSHR (0.42) | HTR2C | |
| SCHEMBL3939166 | 0.67 | ADRA2A (0.32) | — | |
| SCHEMBL2655668 | 0.64 | PLAU (0.42) | MAPTNPC1AHRPDK2KDM4E | |
| SCHEMBL429453 | 0.64 | ALOX15 (0.43) | MAPTNPC1AHRPDK2KDM4E | |
| SCHEMBL447750 | 0.64 | NPC1 (0.34) | MAPTNPC1AHRPDK2KDM4E | |
| SCHEMBL209284 | 0.64 | NPC1 (0.34) | MAPTNPC1AHRPDK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2697232-B1 | 6,7-DIHYDROIMIDAZO[2,1-B][1,3]OXAZINE BACTERICIDES | OTSUKA PHARMA CO LTD (JP) | 2016-05-18 | — | — | EP | claimed |
| US-9051333-B2 | 6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-06-09 | — | — | US | claimed |
| US-20140031342-A1 | 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | claimed |
| CN-118076602-A | Heteroaryl-acetylenes, pharmaceutical compositions thereof and their therapeutic uses | 嘉兴优博生物技术有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-3010943-B1 | CURABLE COMPOSITION, FILM, AND METHOD OF PRODUCING FILM | CANON KK (JP) | 2024-04-03 | — | — | EP | disclosed |
| EP-4316850-A1 | ELECTRON BEAM CURING INKJET INK, INK SET, AND IMAGE RECORDING METHOD | FUJIFILM Corporation (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-11890288-B2 | Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-02-06 | — | — | US | disclosed |
| US-20240018374-A1 | INK JET INK FOR ELECTRON BEAM CURING, INK SET, AND IMAGE RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2024-01-18 | — | — | US | disclosed |
| CN-117203196-A | PDE4 degrading agents, pharmaceutical compositions and therapeutic applications | 拜欧斯瑞克斯公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-4286163-A1 | ELECTRON BEAM-CURABLE INK, AND IMAGE RECORDING METHOD | FUJIFILM Corporation (JP) | 2023-12-06 | — | — | EP | disclosed |
| US-20230364105-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-16 | — | — | US | disclosed |
| US-20070004823-A1 | Ink composition, image forming method and printed article | FUJI PHOTO FILM CO., LTD. | 2007-01-04 | — | — | US | disclosed |
| EP-1739141-A1 | Ink composition, image forming method and printed article | Fuji Photo Film Co., Ltd. (JP) | 2007-01-03 | — | — | EP | disclosed |
| US-20060194029-A1 | Ink composition, inkjet recording method using the same, and printed material | FUJI PHOTO FILM CO., LTD. | 2006-08-31 | — | — | US | disclosed |
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-20040209913-A1 | e.g., 3-[1-(3,5-Dichloroisonicotinoyl)-2,3-dihydro-1 H-indol-5-yl]-2-[(3-oxo-spiro[3.5]non-1-en-1-yl)amino]-propanoate; modulating cell adhesion for the prophylaxis or treatment of inflammatory diseases or disorders, such as rheumatoid arthritis, in which the extravasculation of leukocytes plays a role. | UCB PHARMA S.A. (BE) | 2004-10-21 | — | — | US | disclosed |
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039795-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | WO | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11890288-B2 | Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof | BRD4, BRD1, BRD2 | MAPT 2004/4885NPC1 3907/4885AHR 1870/4885 |
| US-20230364105-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | BRD4, BRD1, BRD2 | MAPT 2004/4885NPC1 3907/4885AHR 1870/4885 |
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | MAPT 4101/4885NPC1 34/4885AHR 55/4885 |
| US-20140031342-A1 | 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES | BRD1, OXA1L, QDPR | MAPT 3136/4885NPC1 3212/4885AHR 546/4885 |
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | MAPT 4202/4885NPC1 100/4885AHR 56/4885 |
| US-20040209913-A1 | e.g., 3-[1-(3,5-Dichloroisonicotinoyl)-2,3-dihydro-1 H-indol-5-yl]-2-[(3-oxo-spiro[3.5]non-1-en-1-yl)amino]-propanoate; modulating cell adhesion for the prophylaxis or treatment of inflammatory diseases or disorders, such as rheumatoid arthritis, in which the extravasculation of leukocytes plays a role. | ICAM1, VCAM1, CCR1 | MAPT 4346/4885NPC1 2595/4885AHR 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.